文献速递核素与放射性配体治疗肿瘤 PET/CT

基线癌胚抗原(CEA)是接受177Lu-PSMA治疗的转移性去势抵抗性前列腺癌(mCRPC)患者的独立预后生物标志物

Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-09-11

该前瞻性观察研究纳入142例接受177Lu-PSMA治疗的mCRPC患者,基线采集血样分析常规实验室标志物。中位随访44.0个月时,中位PFS和OS分别为7.0和16.8个月;基线CEA升高与更短的PFS(p=0.026)和OS(p=0.003)独立相关,且CEA联合PSA较单用PSA改善预后区分度。结论支持基线CEA作为有前景的预后生物标志物。

要点

  • 基线CEA升高与接受177Lu-PSMA治疗的mCRPC患者更短的PFS和OS独立相关。
  • CEA联合PSA较单用PSA改善预后区分度。
  • 基线CEA有望辅助筛选可从177Lu-PSMA治疗中获得临床获益的最佳候选者。

核心结论

  • 基线CEA是接受177Lu-PSMA治疗的mCRPC患者PFS和OS的独立预后因素。

研究设计与样本

  • 前瞻性生物观察性研究纳入142例接受177Lu-PSMA治疗的mCRPC患者,基线采集血样。
  • 采用单变量和多变量Cox回归分析评估血红蛋白、碱性磷酸酶、PSA和CEA等常规实验室标志物与PFS和OS的关联。

主要发现

  • 中位随访44.0个月时,中位PFS为7.0个月,中位OS为16.8个月。
  • 基线CEA升高与更短的PFS独立相关(p=0.026)。
  • 基线CEA升高与更短的OS独立相关(p=0.003)。
  • CEA联合PSA较单用PSA改善预后区分度。

临床怎么用

  • 在177Lu-PSMA治疗前可检测基线CEA,结合PSA用于预后分层和候选患者筛选。
  • 基线CEA升高提示PFS和OS可能较短,可辅助临床决策与随访强度制定。

局限性

  • 需进一步研究验证CEA的预后价值并确定其是否具有预测效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 177Lu-PSMA is currently approved for metastatic castration-resistant prostate cancer (mCRPC). However, only a subset of eligible patients derives a meaningful clinical benefit from treatment. To date, there is a lack of validated biomarkers that could help find the best candidates for this radioligand therapy (RLT). METHODS: 142 patients undergoing 177Lu-PSMA therapy were enrolled in a biological observational prospective study, with blood samples collected at baseline for analysis. Clinical characteristics and routinely available laboratory biomarkers - including hemoglobin, alkaline phosphatase, prostate-specific antigen (PSA), and carcinoembryonic antigen (CEA) - were evaluated by uni- and multivariable Cox regression analyses for their association with progression-free survival (PFS) and overall survival (OS). RESULTS: At a median follow-up of 44.0 months, median PFS and OS were 7.0 and 16.8 months, respectively. Elevated baseline CEA was independently associated with shorter PFS (p = 0.026) and OS (p = 0.003). Moreover, combining CEA with PSA improved prognostic discrimination compared with PSA alone. CONCLUSION: Baseline CEA was independently associated with shorter PFS and OS, supporting its role as a promising prognostic biomarker for patients with mCRPC undergoing 177Lu-PSMA therapy. Further studies are warranted to validate its prognostic value and determine whether it also has predictive utility.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Giunta EF, Marini I, Grassi I, et al. Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy. Eur J Nucl Med Mol Imaging. 2026. PMID: 42722919. doi:10.1007/s00259-026-08173-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。